Scorpius Holdings Inc (SCPX) Return on Assets ROA from the third quarter of 2025 to third quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
Scorpius Holdings Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Scorpius Holdings Inc 's ROA in the third quarter of 2025?
Scorpius Holdings Inc recorded a cumulative net loss of $-27 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -104.73%.
However, within the Healthcare sector 768 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4392, from total ROA ranking in the second quarter of 2025 at 4490.
In a strategic move aimed at bolstering its financial health, Scorpius Holdings Inc. has announced the implementation of significant cost savings measures projected to save the company over $2 million annually. This decision follows a troubling financial trajectory, during which Scorpius recorded a cumulative net loss of $28 million in the 12 months ending in the second quarter of 2024. As a result, the company reported a stark negative return on assets (ROA) of -56.32%.Despite the grim figures, Scorpius Holdings has notably achieved the highest return on assets within the Healthcare sector, suggesting that, relative to its peers, the company s operational efficiency measures may hold potential for stabilization in an otherwise challenging environment. However, the overall ranking for ROA has remained unchanged relative to the first quarter of 2024, indicating persistent hurdles that continue to affect its financial performance.
Scorpius Holdings Joins Medical CBRN Defense Consortium to Enhance U.S. Countermeasure Capabilities Durham, N.C. October 2, 2024 Scorpius Holdings, Inc. an integrated contract development and manufacturing organization (CDMO), has announced its selection to join the Medical CBRN Defense Consortium (MCDC). This strategic move positions Scorpius Holdings as a significant contributor within a key initiative aimed at bolstering the United States defense against chemical, biological, radiological, and nuclear threats. The Role of the MCDC The Medical CBRN Defense Consortium is an organization focused on advancing the development of medical countermeasures and related technologies that are critical for the protection of U.S. military personnel and civilians. By bringing together government, industry, and academia, the consortium works to accelerate the delivery of innovative medical solutions to safeguard against CBRN threats.
On September 30, 2024, Scorpius Holdings, Inc. (NYSE American: SCPX), a prominent integrated contract development and manufacturing organization (CDMO), announced a significant contract to provide bioanalytical services for a publicly traded clinical-stage biotech company specializing in immuno-oncology. This collaboration opens up new avenues for Scorpius Holdings, potentially positioning the company as a key player in the growing field of advanced cancer therapies. As immuno-oncology continues to gain traction as a cornerstone in cancer treatment, there is an increasing demand for contract services that support the research and development of innovative therapies. Scorpius Holdings is strategically positioned to leverage its extensive expertise and facilities, enhancing its service offerings in the burgeoning field of immunotherapeutics. The clinical-stage biotech company involved in the contract has been making strides in developing novel treatments that harness the body s immune system to fight cancer. By partnering with a recognized CDMO like Scorpius, the company can streamline its bioanalytical processes, enabling more efficient and reliable outcomes in their drug development pipeline. The synergistic collaboration will bolster both companies’ abilities to respond to regulatory requirements and accelerate time-to-market for their innovative products.Despite this promising development, it is worth noting that Scorpius Holdings’ shares have recently seen volatile performance, currently trading at $0.72 a decline relative to the broader market trends. Throughout September, the company’s stock has lagged behind the overall market, reflecting investors cautious sentiment regarding the firm’s ability to convert recent strategic moves into tangible, positive shareholder value. Analysts and investors remain watchful, as the successful execution of this contract could serve as a crucial pivot point for Scorpius Holdings. If the partnership yields positive results, it may provide a foundation for broader GMP (Good Manufacturing Practices) manufacturing opportunities in the future. The collaboration has the potential to not only elevate the profile of Scorpius Holdings within the biotech community but also to attract additional contracts with other biotech firms looking for reliable development and manufacturing partners.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
